Trial Profile
A tolerability, pharmacokinetics and phamacodynamics phase Ⅰclinical trial of intravenous infusions of Recombinant Neutrophil inhibitory factor and Hirulog Hbrid in healthy volunteers
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Neutrophil inhibitory factor-bivalirudin fusion protein (Primary)
- Indications Stroke
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 01 Jun 2016 New trial record